Monopar Therapeutics Inc. (FRA:1IY0)
Germany · Delayed Price · Currency is EUR | Market Cap | 423.47M -13.9% |
| Revenue (ttm) | n/a |
| Net Income | -15.62M |
| EPS | -1.95 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23 |
| Open | 63.10 |
| Previous Close | 62.40 |
| Day's Range | 63.10 - 63.40 |
| 52-Week Range | 41.70 - 103.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 10, 2026 |
About Monopar Therapeutics
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging ... [Read more]
News
Monopar Therapeutics price target raised to $145 from $128 at Barclays
Barclays raised the firm’s price target on Monopar Therapeutics (MNPR) to $145 from $128 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Monopar Appoints Jeffrey D. Kent, M.D.
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for...
Monopar Therapeutics price target raised to $130 from $115 at Morgan Stanley
Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Monopar Therapeutics (MNPR) to $130 from $115 and keeps an Overweight rating on the shares.
Monopar Therapeutics reports Q2 EPS (62c), consensus (65c)
On July 22, Monopar announced it had initiated the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for ALXN1840. The FDA authorized Monopar to…
Monopar Therapeutics sees cash runway through December 31, 2027
Cash, cash equivalents and investments as of June 30, were $134.3M. Monopar expects its current funds to support operations through at least December 31, 2027, including: regulatory and potential comm...
Monopar Therapeutics price target raised to $133 from $117 at BTIG
BTIG analyst Jeet Mukherjee raised the firm’s price target on Monopar Therapeutics (MNPR) to $133 from $117 and keeps a Buy rating on the shares following Q2 earnings. The firm…
Monopar Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska downgraded Monopar Therapeutics (MNPR) to Neutral from Overweight with a price target of $119, up from $109.
Monopar Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska downgraded Monopar Therapeutics (MNPR) to Neutral from Overweight with a price target of $119, up from $109, following the Q2 report. The firm still likes…
Monopar Therapeutics price target raised to $128 from $125 at Barclays
Barclays raised the firm’s price target on Monopar Therapeutics (MNPR) to $128 from $125 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for...
Monopar Therapeutics Quarterly report: Q2 2026
Monopar Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Monopar Therapeutics Earnings release: Q2 2026
Monopar Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Monopar price target raised to $125 from $105 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $125 from $105 and keeps a Buy rating on the shares after the company said it initiated the…
Monopar Therapeutics initiates rolling ALXN1840 NDA submission to FDA
Monopar Therapeutics (MNPR) announced that it has initiated the rolling submission of a new drug application, or NDA, to the FDA for ALXN1840, its albumin tripartite complex activator for the…
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for...
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for...
Monopar Therapeutics price target raised to $117 from $104 at BTIG
BTIG analyst Jeet Mukherjee raised the firm’s price target on Monopar Therapeutics (MNPR) to $117 from $104 and keeps a Buy rating on the shares. Monopar has an improved regulatory…
Monopar Therapeutics receives Rare Pediatric Disease designation for ALXN1840
Monopar Therapeutics (MNPR) announced that the FDA has granted Rare Pediatric Disease designation to ALXN1840, the company’s late-stage candidate for the treatment of Wilson disease.
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for...
Monopar Therapeutics price target raised to $117 from $104 at BTIG
BTIG analyst Jeet Mukherjee raised the firm’s price target on Monopar Therapeutics (MNPR) to $117 from $104 and keeps a Buy rating on the shares. Monopar has an improved regulatory…
Monopar Therapeutics announces new FoCus trial analyses
Monopar Therapeutics (MNPR) announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 will be presented at the 12th Congress of the European Academy of…
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for...
Monopar Therapeutics management to meet virtually with Piper Sandler
Virtual Meeting to be held on June 23 hosted by Piper Sandler.
Monopar Therapeutics Slides: Corporate presentation
Monopar Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Monopar Therapeutics presents ALXN1840-WD-205 data at EASL
Monopar Therapeutics (MNPR) announced the presentation of Phase 2 ALXN1840-WD-205 data at the European Association for the Study of the Liver, or EASL, Congress 2026. In a presentation, the company…